The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
Tobias Dreyer(Technical University of Munich), Holger Bronger(Technical University of Munich)
Cited by 23
Related Papers
Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
|Clinical Cancer Research|2012|124
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
|Gynecologic Oncology|2019|121
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
|British Journal of Cancer|2022|69